1. Bladder Cancer: A New Era in Treatment

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Overview of Bladder Cancer

4. Systemic Therapy for Bladder Cancer Feb 2016

5. Rationale for the Use of Immunotherapy in UC

6. Second-Line Therapy for Advanced UC Keynote-045: Pembrolizumab

7. Progression-Free Survival Keynote-045: Pembrolizumab

8. Overall Survival Keynote-045: Pembrolizumab

9. Overall Survival in PD-L1 Subpopulation Keynote-045: Pembrolizumab

10. TRAEs With Incidence ≥15%

11. HRQoL in Advanced UC Patients Keynote-045: Pembrolizumab

12. Phase 2 Study of Nivolumab in mUC CheckMate 275: Safety

13. Phase 2 Study of Nivolumab in mUC CheckMate 275: Efficacy

14. Phase 1a Study of Atezolizumab in mUC Two-Year Clinical Update

15. Update on Efficacy and Tolerability of Durvalumab in mUC

16. Phase 1b Study of Avelumab in mUC JAVELIN: Two Pooled Cohorts

17. Post-Platinum Treatment Summary

18. Treatment for Cisplatin-Ineligible mUC Patients IMvigor 210: Atezolizumab Phase 2 Study

19. Treatment for Cisplatin-Ineligible mUC Patients Keynote-052: Pembrolizumab Phase 2 Study

20. First-Line Cisplatin-Ineligible Patients Treatment Summary

21. Nivolumab plus Ipilimumab Treatment in mUC CheckMate 032: Efficacy

22. Nivolumab plus Ipilimumab Treatment in mUC CheckMate 032: Safety

23. Ongoing Phase 3 Studies

24. Immune-Related Adverse Effects

25. Safety Learnings From Nivolumab in Melanoma

26. Kinetics of Onset and Resolution of Treatment-Related Toxicities

27. Key Takeaways

28. Current Treatment Approach in the Clinic

29. Abbreviations

30. Abbreviations (cont)